| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993471 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(6 years from now) | |
| US8829005 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(6 years from now) | |
| US9750684 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(6 years from now) | |
|
US8829005 (Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(6 years from now) | |
| US9254286 | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(8 years from now) | |
|
US9254286 (Pediatric) | EYEVANCE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(9 years from now) | |
Zerviate is owned by Eyevance.
Zerviate contains Cetirizine Hydrochloride.
Zerviate has a total of 6 drug patents out of which 0 drug patents have expired.
Zerviate was authorised for market use on 30 May, 2017.
Zerviate is available in solution/drops;ophthalmic dosage forms.
Zerviate can be used as treatment of ocular itching associated with allergic conjunctivitis.
The generics of Zerviate are possible to be released after 09 January, 2033.
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZERVIATE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic